Loading...
Market
What will be the outcome of Moderna's 2025 cash cost expense reduction?
2
Resolution / Starting Odds
Achieves $1 billion reduction • 25%
Exceeds $1 billion reduction • 25%
Fails to achieve $1 billion reduction • 25%
Other • 25%
Moderna's official financial statements and earnings reports
Story
Moderna Lowers 2025 Revenue Forecast to $1.5B–$2.5B; Shares Plunge 20% Pre-Market
Jan 13, 2025, 12:31 PM
Moderna Inc. lowered its 2025 revenue forecast to a range of $1.5 billion to $2.5 billion, down from previous estimates of $2.5 billion to $3.5 billion and below analysts' expectations of $2.95 billion, due to slower-than-expected demand for its COVID-19 and RSV vaccines. The company also reported 2024 product sales of $3.0 to $3.1 billion and an ending cash balance of approximately $9.5 billion. In response to the reduced revenue outlook, Moderna plans to reduce its 2025 cash cost expenses by $1 billion and intends to implement additional cost reductions of $500 million in 2026. CEO Stéphane Bancel highlighted the company's focus on driving growth, with a pipeline of 10 vaccines. Following the announcement, Moderna's stock plunged up to 20% in pre-market trading, reaching its lowest levels since April 2020.
View original story
Similar markets
More than $7B • 25%
Less than $5B • 25%
$5B to $6B • 25%
$6B to $7B • 25%
No • 50%
Yes • 50%
0-2 • 25%
3-4 • 25%
5-6 • 25%
More than 6 • 25%
Increase by 10% to 20% • 25%
Increase by less than 10% • 25%
Increase by more than 20% • 25%
Decrease • 25%
No significant change • 25%
Increase > 5% • 25%
Fluctuate within 5% • 25%
Decrease > 5% • 25%
$500 billion to $1 trillion • 25%
Less than $500 billion • 25%
$1 trillion to $2 trillion • 25%
More than $2 trillion • 25%
More than 350,000 rubles • 25%
Less than 300,000 rubles • 25%
Exactly 300,000 rubles • 25%
301,000 to 350,000 rubles • 25%
$2.86 - $2.90 • 25%
$2.96 - $3.00 • 25%
$2.80 - $2.85 • 25%
$2.91 - $2.95 • 25%